3B Blackbio DX Ltd
3B Blackbio DX (previously known as Kilpest India) is into Crop protection, Public health products and bio-products and is also a supplier to various Govt. organizations, such as FCI (Food Corporation of India), NTPC (National Thermal Power Corporation Limited), Railway, etc. The company is also exporting its products to Bangladesh and Afghanistan.
The company entered into molecular diagnostics with 3B BlackBio BiotechIndia Ltd. [1][2]
- Market Cap ₹ 600 Cr.
- Current Price ₹ 798
- High / Low ₹ 924 / 390
- Stock P/E 21.6
- Book Value ₹ 278
- Dividend Yield 0.31 %
- ROCE 19.1 %
- ROE 16.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 49.9% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 44.5%
- Promoter holding has increased by 2.86% over last quarter.
Cons
- Company has high debtors of 200 days.
- Working capital days have increased from 161 days to 248 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
21 | 20 | 22 | 19 | 17 | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 69 | |
20 | 19 | 21 | 18 | 16 | 14 | 18 | 16 | 20 | 77 | 44 | 33 | 39 | |
Operating Profit | 1 | 1 | 1 | 1 | 2 | 3 | 5 | 7 | 9 | 150 | 37 | 29 | 31 |
OPM % | 5% | 6% | 6% | 7% | 9% | 16% | 23% | 31% | 32% | 66% | 46% | 47% | 44% |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 7 | 7 | 9 | |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Profit before tax | 0 | 1 | 0 | 0 | 0 | 1 | 5 | 7 | 10 | 152 | 43 | 35 | 39 |
Tax % | 104% | 34% | 14% | 23% | 23% | 19% | 24% | 25% | 23% | 25% | 26% | 27% | |
-0 | 0 | 0 | 0 | 0 | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 28 | |
EPS in Rs | -0.02 | 0.62 | 0.59 | 0.36 | 0.51 | 1.76 | 5.35 | 8.18 | 10.24 | 151.66 | 42.89 | 34.55 | 37.79 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 17% | 9% | 6% | 7% | 6% | 24% | 7% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 22% |
3 Years: | 29% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | 52% |
5 Years: | 50% |
3 Years: | 50% |
TTM: | 20% |
Stock Price CAGR | |
---|---|
10 Years: | 60% |
5 Years: | 56% |
3 Years: | 23% |
1 Year: | 82% |
Return on Equity | |
---|---|
10 Years: | 39% |
5 Years: | 43% |
3 Years: | 44% |
Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 7 | 9 |
Reserves | 3 | 3 | 4 | 4 | 4 | 5 | 12 | 16 | 25 | 125 | 146 | 164 | 200 |
6 | 6 | 7 | 8 | 8 | 9 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | |
7 | 7 | 7 | 7 | 6 | 6 | 6 | 8 | 9 | 59 | 37 | 41 | 15 | |
Total Liabilities | 22 | 23 | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 225 |
4 | 4 | 4 | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 7 | 8 | 8 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 59 | 93 | 92 | 96 |
18 | 19 | 20 | 21 | 21 | 22 | 26 | 32 | 40 | 130 | 93 | 114 | 122 | |
Total Assets | 22 | 23 | 24 | 25 | 24 | 26 | 30 | 36 | 45 | 194 | 192 | 214 | 225 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | -1 | 0 | 0 | 1 | 1 | 2 | 4 | 7 | 98 | 37 | 23 | |
-1 | 0 | -0 | -0 | -0 | -0 | -1 | -1 | -1 | -70 | -28 | 12 | |
1 | -0 | 0 | -0 | -1 | -0 | 0 | -1 | 1 | -2 | -15 | -5 | |
Net Cash Flow | 1 | -1 | 0 | -0 | 0 | 0 | 1 | 2 | 7 | 26 | -6 | 30 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 180 | 220 | 213 | 262 | 283 | 321 | 259 | 290 | 252 | 56 | 136 | 200 |
Inventory Days | 109 | 149 | 120 | 145 | 143 | 175 | ||||||
Days Payable | 165 | 220 | 189 | 218 | 203 | 186 | ||||||
Cash Conversion Cycle | 124 | 149 | 144 | 188 | 223 | 310 | 259 | 290 | 252 | 56 | 136 | 200 |
Working Capital Days | 167 | 214 | 218 | 274 | 312 | 377 | 308 | 351 | 302 | 67 | 169 | 248 |
ROCE % | 7% | 8% | 7% | 7% | 7% | 13% | 24% | 28% | 31% | 162% | 27% | 19% |
Documents
Announcements
- Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 19m
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 4h
- Submission Of Compliance Certificate Under Regulation 40(9) Of The SEBI (LODR) Regulations, 2015 For The Financial Year Ended 31-03-2024 15 Apr
- Disclosure Under Reg 32(1) Of SEBI (LODR) Regulations,2015 8 Apr
- Compliance Certificate- Regulation 7(3) OF SEBI (LODR) Regulations, 2015. 5 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Sep 2021TranscriptNotesPPT
-
Jul 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Sep 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Jul 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
3B BlackBio Biotech India Limited (Subsidiary)[1]
Incorporated in 2011, “3B BlackBio Biotech India Limited”, a subsidiary of Kilpest India Limited, is engaged in Design, Development Manufacturing and Commercialization of qPCR tests, Rapid tests, NGS based Molecular Diagnostic Kits and Extraction Kits. The company has the largest range of CE-IVD products in the molecular diagnostics segment.
Brands: TRUPCR, TRURAPID, truNGS, TRUPCR Europe.